Form 4: Athira Pharma CEO Mark Litton Acquires Stock Options and Restricted Stock Units

Mark Litton, CEO of Athira Pharma, acquired stock options for 333,815 shares and 222,543 restricted stock units on March 3, 2025.

Summary

• On March 3, 2025, Mark James Litton, the President and CEO of Athira Pharma, Inc. [ATHA], acquired stock options and restricted stock units (RSUs).
• Litton acquired options for 333,815 shares of common stock at an exercise price of $0.3762 per share.
• These options vest monthly over 48 months, starting from the grant date, contingent upon continued service.
• Additionally, Litton acquired 222,543 RSUs, each representing a right to receive one share of Athira Pharma's common stock.
• The RSUs vest 100% on the one-year anniversary of the grant date, also contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The vesting schedules suggest a long-term commitment from the CEO.

Positives

• The acquisition of stock options and RSUs by the CEO aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment and performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the options and RSUs.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules, such as the 48-month monthly vesting for the options and one-year cliff vesting for the RSUs, are typical for incentivizing long-term performance.
• Comparing the size of the grant to those of CEOs at similarly sized biotech companies (e.g., companies with similar market capitalization and stage of drug development) would provide further context.

Stakeholder Impact

• The grants align the CEO's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Athira Pharma, Mark Litton, stock options, restricted stock units, RSUs, insider trading, Form 4, executive compensation, equity incentive plan